Halozyme Therapeutics, Inc.

BMV:HALO * Stock Report

Market Cap: Mex$88.8b

Halozyme Therapeutics Management

Management criteria checks 1/4

Halozyme Therapeutics' CEO is Helen Torley, appointed in Jan 2014, has a tenure of 9.92 years. total yearly compensation is $9.70M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth MX$419.22M. The average tenure of the management team and the board of directors is 1.9 years and 9.9 years respectively.

Key information

Helen Torley

Chief executive officer

US$9.7m

Total compensation

CEO salary percentage9.0%
CEO tenure9.9yrs
CEO ownership0.5%
Management average tenure1.9yrs
Board average tenure9.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Helen Torley's remuneration changed compared to Halozyme Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

US$254m

Jun 30 2023n/an/a

US$234m

Mar 31 2023n/an/a

US$182m

Dec 31 2022US$10mUS$872k

US$202m

Sep 30 2022n/an/a

US$211m

Jun 30 2022n/an/a

US$366m

Mar 31 2022n/an/a

US$435m

Dec 31 2021US$7mUS$830k

US$403m

Sep 30 2021n/an/a

US$409m

Jun 30 2021n/an/a

US$229m

Mar 31 2021n/an/a

US$163m

Dec 31 2020US$7mUS$791k

US$129m

Sep 30 2020n/an/a

US$22m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$80m

Dec 31 2019US$6mUS$761k

-US$72m

Sep 30 2019n/an/a

-US$40m

Jun 30 2019n/an/a

-US$43m

Mar 31 2019n/an/a

-US$51m

Dec 31 2018US$6mUS$725k

-US$80m

Sep 30 2018n/an/a

US$46m

Jun 30 2018n/an/a

US$76m

Mar 31 2018n/an/a

US$68m

Dec 31 2017US$5mUS$671k

US$63m

Sep 30 2017n/an/a

-US$88m

Jun 30 2017n/an/a

-US$120m

Mar 31 2017n/an/a

-US$116m

Dec 31 2016US$5mUS$645k

-US$103m

Compensation vs Market: Helen's total compensation ($USD9.70M) is above average for companies of similar size in the MX market ($USD2.79M).

Compensation vs Earnings: Helen's compensation has increased by more than 20% in the past year.

CEO

Helen Torley (60 yo)

9.9yrs

Tenure

US$9,696,978

Compensation

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the...

Leadership Team

NamePositionTenureCompensationOwnership
Helen Torley
President9.9yrsUS$9.70m0.47%
MX$ 419.2m
Nicole LaBrosse
Senior VP & CFO1.8yrsUS$2.73m0.0069%
MX$ 6.1m
Michael LaBarre
Senior VP & Chief Technical Officerno dataUS$3.12m0.12%
MX$ 102.1m
Mark Snyder
Chief Legal Officer1.9yrsUS$3.74m0.0036%
MX$ 3.2m
Cortney Caudill
Chief Operations Officerless than a yearno datano data
Tram Bui
Head of Investor Relations & Corporate Communications1.9yrsno datano data
Amy Fox
Chief Human Resources Officer3.9yrsno datano data
Steve Knowles
Chief Medical Officer3.8yrsno datano data
Christopher Bryant
Chief Manufacturing Officer & Head of Technical Operations2.8yrsno datano data
Kristin Schwartzbauer
Head of Qualityno datano datano data
Gary Grote
Chief Commercial Officerless than a yearno datano data
Christopher Wahl
Chief Business Officerless than a yearno datano data

1.9yrs

Average Tenure

59.5yo

Average Age

Experienced Management: HALO *'s management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Helen Torley
President9.9yrsUS$9.70m0.47%
MX$ 419.2m
Connie Matsui
Independent Director17.4yrsUS$333.50k0.14%
MX$ 120.3m
Jeffrey Henderson
Independent Chair of the Board8.3yrsUS$382.72k0.030%
MX$ 26.2m
Daniel Von Hoff
Member of the Scientific Advisory Board19.3yrsno datano data
Jeffrey Bleil
Member of the Advisory Boardno datano datano data
Gregory Frost
Chairman of Scientific Advisory Board9.9yrsUS$68.17kno data
Gerhard Baumgartner
Member of Scientific Advisory Board19.5yrsno datano data
James Daly
Independent Director8.9yrsUS$316.76k0.0094%
MX$ 8.4m
Sue Bailey
Member of Scientific Advisory Board18.4yrsno datano data
Matthew Posard
Independent Director10.8yrsUS$325.04k0.080%
MX$ 70.7m
Jean-Pierre Bizzari
Independent Director8.9yrsUS$315.04k0.044%
MX$ 39.5m
Bernadette Connaughton
Independent Director5.3yrsUS$320.04k0.024%
MX$ 21.7m

9.9yrs

Average Tenure

65yo

Average Age

Experienced Board: HALO *'s board of directors are considered experienced (9.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/20 00:22
End of Day Share Price 2023/09/22 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Halozyme Therapeutics, Inc. is covered by 34 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Robert WassermanBenchmark Company